Showing 41 - 60 results of 15,701 for search 'treating data', query time: 0.09s Refine Results
  1. 41
  2. 42
  3. 43

    Analysis of 5-year clinical and radiological outcomes in patients with psoriatic arthritis observed as part of the Treat to target strategy. Preliminary data by P. O. Tremaskina, E. Yu. Loginova, T. V. Korotaeva, S. I. Glukhova, A. V. Sukhinina, A. V. Smirnov, A. M. Lila

    Published 2022-06-01
    “…Objective: to analyze preliminary data on 5-year clinical and radiographic outcomes in patients with early psoriatic arthritis (PsA) observed as part of the Treat to target (T2T) strategy.Patients and methods. …”
    Get full text
    Article
  4. 44
  5. 45
  6. 46
  7. 47

    Genomic sequence data of Thiohalocapsa marina: a sulfur-oxidizing bacterium prevalent in treated municipal wastewater and commercial shrimp hatchery effluents by Guillermo Reyes, Irma Betancourt, Betsy Andrade, Yessenia Pozo, Lita Sorroza, Luis E. Trujillo, Bonny Bayot

    Published 2025-03-01
    “…This study enhances the understanding of the ecological adaptation and bioremediation capabilities of Thc. marina in treated municipal wastewater effluents. Data description We present a draft genome of Thc. marina LNA26 recovered from treated municipal wastewater effluents using shotgun metagenomic sequencing. …”
    Get full text
    Article
  8. 48

    Comparison of programmatic data from antenatal clinics with population-based HIV prevalence estimates in the era of universal test and treat in western Kenya. by Julie Ambia, Julio E Romero-Prieto, Daniel Kwaro, Kathryn Risher, Sammy Khagayi, Clara Calvert, David Obor, Malebogo Tlhajoane, Fredrick Odongo, Milly Marston, Emma Slaymaker, Brian Rice, Chodziwadziwa Whiteson Kabudula, Jeffrey W Eaton, Georges Reniers

    Published 2023-01-01
    “…<h4>Objective</h4>To compare HIV prevalence estimates from routine programme data in antenatal care (ANC) clinics in western Kenya with HIV prevalence estimates in a general population sample in the era of universal test and treat (UTT).…”
    Get full text
    Article
  9. 49
  10. 50
  11. 51

    Predefined and data-driven CT radiomics predict recurrence-free and overall survival in patients with pulmonary metastases treated with stereotactic body radiotherapy. by Pascal Salazar, Patrick Cheung, Balaji Ganeshan, Anastasia Oikonomou

    Published 2024-01-01
    “…<h4>Methods</h4>111 patients with 163 metastases treated with SBRT were included with a median follow-up time of 927 days. …”
    Get full text
    Article
  12. 52

    Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network by Henner Zirpel, Ralf J. Ludwig, Henning Olbrich, Khalaf Kridin, Sascha Ständer, Diamant Thaçi

    Published 2024-12-01
    “…In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.Conclusion Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. …”
    Get full text
    Article
  13. 53
  14. 54

    Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer by Furnback W, Wu E, Koh CYC, Nino de Rivera Guzman JF, Kruhl C, Kotecha R, Wang BC

    Published 2025-02-01
    “…TTFields therapy extended mean lifetime survival, offering a clinically meaningful and economically justifiable option for patients progressing after platinum-based chemotherapy.Plain language summary: Recent clinical data from the LUNAR study has shown that Tumor Treating Fields (TTFields) therapy concomitant with immune checkpoint inhibitors (ICIs) or docetaxel improves survival in patients with metastatic non-small cell lung cancer (NSCLC) on or after platinum-based therapy. …”
    Get full text
    Article
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59

    Optimization of Tumor Treating Fields (TTFields) Frequency and Treatment Duration in Colorectal Cancer Cells by Menglan Liu, Zhaoran Su, Paul‐Philipp Hagemann, Malte Fischer, Michael Linnebacher

    Published 2025-05-01
    “…Cell viability was assessed after 72 h using crystal violet staining and spectrophotometry. Data were analyzed using t‐tests or ANOVA, with p < 0.05 considered statistically significant. …”
    Get full text
    Article
  20. 60

    Optune in Glioblastoma: Revolutionizing Treatment with Tumor Treating Fields by Patrycja Długozima, Klaudia Mączewska, Dominika Hakało, Julia Kozakiewicz, Kamil Kościelecki, Agnieszka Kalisz, Iwona Skorulska, Paulina Grzeszczuk, Weronika Grywińska, Aleksandra Głowacka

    Published 2025-05-01
    “…In recent years, Tumor Treating Fields (TTFields), commercially known as Optune, have emerged as an innovative, non-invasive therapeutic approach. …”
    Get full text
    Article